Skip to Content

Nivolumab BMS

Active Substance: nivolumab
Common Name: nivolumab
ATC Code: L01XC17
Marketing Authorisation Holder: Bristol-Myers Squibb Pharma EEIG
Active Substance: nivolumab
Status: Withdrawn
Authorisation Date: 2015-07-20
Therapeutic Area: Carcinoma, Non-Small-Cell Lung
Pharmacotherapeutic Group: Antineoplastic and immunomodulating agents, monoclonal antibodies

Therapeutic Indication

Nivolumab BMS is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.

The marketing authorisation for Nivolumab BMS has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.